AstraZeneca and Daiichi Sankyo withdraw EU marketing application for lung cancer treatment

From NASDAQ.: 2024-12-24 02:26:38

AstraZeneca and Daiichi Sankyo have withdrawn their marketing authorization application in the EU for datopotamab deruxtecan for the treatment of lung cancer. Despite the withdrawal, they are committed to making the medicine available to patients through their clinical development program. The application for the treatment of breast cancer remains under review. Datopotamab deruxtecan is a TROP2-directed antibody drug conjugate. For more health news, visit rttnews.com.



Read more at NASDAQ.: AstraZeneca And Daiichi Sankyo Withdraw EU Marketing Application For Datopotamab Deruxtecan